Project abstract for group dings


The US Food and Drug Administration’s approval of new anti-cancer agents has decreased over the past decade, and although angiogenesis inhibitors have shown great initial results in tumor mouse models, clinically they have not lived up to their promise. While tumor endothelial cells were initially perceived as less prone to become resistant, we now know that they actually have a high degree of plasticity and are able to become resistant or develop compensatory mechanisms. These researchers are working to develop a new platform methodology, involving deep sequencing, in drug-resistance discovery embedded within in the angiogenesis and tumor microenvironment field.